Improvement of impulse control disorders associated with levodopa–carbidopa intestinal gel treatment in advanced Parkinson’s disease
Authors:
- On behalf of the EDIS Study GroupOGOn behalf of the EDIS Study Group
- Maria Jose CatalanMCMaria Jose Catalan
- 20 March 2018
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 265 (6) , 1279-1287
Abstract
Impulse control behaviors are a frequent comorbidity for patients with Parkinson’s disease (PD). The objective of the present study was to evaluate the effectiveness levodopa–carbidopa intestinal gel (LCIG) therapy on impulse control disorders (ICDs) in patients with advanced PD. We conducted a multicenter, observational, and prospective (6 months follow-up) study that included consecutive PD patients assigned to LCIG through routine medical practice. Patients completed visits at baseline, 1, 3, and 6 months after percutaneous endoscopic gastrostomy procedure. The following outcomes were evaluated: presence and severity of ICDs and other neuropsychiatric disorders, sleep disturbances, patients’ quality of life, and caregivers’ burden. Sixty-two patients were included at baseline: mean age 72.2 years (SD ± 7.0), 42% women. Median duration of PD symptoms was 13.5 years (IQR 5.5–21.5) and median time with motor fluctuations was 5.0 years (IQR 1.0–9.0). Treatment with LCIG infusion was associated with progressive and significant improvements in ICDs symptoms over the study period (64.4% reduction in the Questionnaire for Impulsive–Compulsive Disorders in Parkinson’s disease—Rating Scale score). Psychotic and other neuropsychiatric symptoms were also significantly reduced, and patients’ sleep quality and psychosocial function improved. Caregivers’ burden remained unchanged. There was a significant improvement in the daily “Off” time [7.4 h (SD ± 4.0) vs 1.5 h (SD ± 1.8); p < 0.0001] at the end of follow-up, whereas duration of dyskinesias was not affected. ICDs significantly improved after 6-month LCIG treatment in a group of PD patients with mild-to-moderate neuropsychiatric disturbances.Keywords
Funding Information
- AbbVie Spain
- Foundation Neurociencias y Envejecimiento
This publication has 39 references indexed in Scilit:
- Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s diseaseJournal of Clinical Neuroscience, 2016
- Neuropsychiatric symptoms and caregiver's burden in Parkinson's diseaseParkinsonism & Related Disorders, 2015
- Effect of impulse control disorders on disability and quality of life in Parkinson’s disease patientsJournal of Clinical Neuroscience, 2014
- Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregiversNeurology, 2013
- A short Scale for Evaluation of Neuropsychiatric Disorders in Parkinson’s Disease: first psychometric approachJournal of Neurology, 2012
- The impact of sleep and mood disorders on quality of life in Parkinson’s disease patientsJournal of Neurology, 2011
- Impulse Control Disorders in Parkinson DiseaseArchives of Neurology, 2010
- Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task forceMovement Disorders, 2007
- Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson’s diseaseExpert Review of Neurotherapeutics, 2006
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992